Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    January 2017
  1. DEAN M, Davis DA, Burdette JE
    Activin A Stimulates Migration of the Fallopian Tube Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical Signaling.
    Cancer Lett. 2017 Jan 20. pii: S0304-3835(17)30034.
    PubMed     Text format     Abstract available


    December 2016
  2. LUO T, Sun J, Zhu S, He J, et al
    Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30802.
    PubMed     Text format     Abstract available


  3. AUER K, Bachmayr-Heyda A, Aust S, Grunt TW, et al
    Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
    Cancer Lett. 2016 Dec 7. pii: S0304-3835(16)30739.
    PubMed     Text format     Abstract available


    November 2016
  4. JEONG JY, Kang HY, Kim TH, Kim GI, et al
    MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Cancer Lett. 2016 Nov 22. pii: S0304-3835(16)30705.
    PubMed     Text format     Abstract available


    September 2016
  5. YOU J, Liu J, Bao Y, Wang L, et al
    SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.
    Cancer Lett. 2016 Sep 30. pii: S0304-3835(16)30574.
    PubMed     Text format     Abstract available


    April 2016
  6. LUO Z, Wang Q, Lau WB, Lau B, et al
    Tumor microenvironment: The culprit for ovarian cancer metastasis?
    Cancer Lett. 2016 Apr 27. pii: S0304-3835(16)30274.
    PubMed     Text format     Abstract available


  7. MALEVA KOSTOVSKA I, Wang J, Bogdanova N, Schurmann P, et al
    Rare ATAD5 missense variants in breast and ovarian cancer patients.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30209.
    PubMed     Text format     Abstract available


    March 2016
  8. TONG H, Ke JQ, Jiang FZ, Wang XJ, et al
    Tumor-associated macrophage-derived CXCL8 could induce ERalpha suppression via HOXB13 in endometrial cancer.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30196.
    PubMed     Text format     Abstract available


  9. TANG S, Xiang T, Huang S, Zhou J, et al
    Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling.
    Cancer Lett. 2016 Mar 23. pii: S0304-3835(16)30194.
    PubMed     Text format     Abstract available


    January 2016
  10. AI Z, Lu Y, Qiu S, Fan Z, et al
    Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Cancer Lett. 2016 Jan 19. pii: S0304-3835(16)00021.
    PubMed     Text format     Abstract available


    December 2015
  11. GWAK H, Kim S, Dhanasekaran DN, Song YS, et al
    Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.
    Cancer Lett. 2015 Dec 15. pii: S0304-3835(15)00722.
    PubMed     Text format     Abstract available


    November 2015
  12. SEO JA, Kim B, Dhanasekaran DN, Tsang BK, et al
    Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum ca ATPase activity in ovarian cancer cells.
    Cancer Lett. 2015 Nov 19. pii: S0304-3835(15)00697.
    PubMed     Text format     Abstract available


    September 2015
  13. THIBAULT B, Clement E, Zorza G, Meignan S, et al
    F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
    Cancer Lett. 2015 Sep 23. pii: S0304-3835(15)00586.
    PubMed     Text format     Abstract available


  14. GORODNOVA TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, et al
    High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Cancer Lett. 2015 Sep 2. pii: S0304-3835(15)00569.
    PubMed     Text format     Abstract available


    August 2015
  15. ALTMAN MK, Alshamrani AA, Jia W, Nguyen H, et al
    Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.
    Cancer Lett. 2015 Aug 28. pii: S0304-3835(15)00541.
    PubMed     Text format     Abstract available


    July 2015
  16. HOVER LD, Young CD, Bhola NE, Wilson AJ, et al
    Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.
    Cancer Lett. 2015 Jul 30. pii: S0304-3835(15)00487.
    PubMed     Text format     Abstract available


  17. TANG MK, Wong AS
    Exosomes: Emerging biomarkers and targets for ovarian cancer.
    Cancer Lett. 2015 Jul 17. pii: S0304-3835(15)00456.
    PubMed     Text format     Abstract available


    April 2015
  18. ZHU LY, Zhang WM, Yang XM, Cui L, et al
    Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition.
    Cancer Lett. 2015 Apr 9. pii: S0304-3835(15)00260.
    PubMed     Text format     Abstract available


  19. KREUZINGER C, Gamperl M, Wolf A, Heinze G, et al
    Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Cancer Lett. 2015 Apr 8. pii: S0304-3835(15)00242.
    PubMed     Text format     Abstract available


  20. HUANG CT, Chang MC, Chen YL, Chen TC, et al
    Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation.
    Cancer Lett. 2015;359:117-26.
    PubMed     Text format     Abstract available


    March 2015
  21. LOJKIN I, Rubinek T, Orsulik S, Schwarzmann O, et al
    Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer.
    Cancer Lett. 2015 Mar 27. pii: S0304-3835(15)00237.
    PubMed     Text format     Abstract available


  22. CHEN S, Chen X, Xiu YL, Sun KX, et al
    MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression.
    Cancer Lett. 2015 Mar 25. pii: S0304-3835(15)00221.
    PubMed     Text format     Abstract available


  23. LIU L, Chang S, Sun J, Zhu S, et al
    Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts.
    Cancer Lett. 2015 Mar 6. pii: S0304-3835(15)00167.
    PubMed     Text format     Abstract available


    February 2015
  24. WANG H, Bao W, Jiang F, Che Q, et al
    Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma
    Cancer Lett. 2015 Feb 16. pii: S0304-3835(15)00132.
    PubMed     Text format     Abstract available


  25. SHEN YA, Liu CS, Chang YH, Chen PH, et al
    Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.
    Cancer Lett. 2015 Feb 4. pii: S0304-3835(15)00088.
    PubMed     Text format     Abstract available


    January 2015
  26. CHE YL, Luo SJ, Li G, Cheng M, et al
    The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis.
    Cancer Lett. 2015 Jan 21. pii: S0304-3835(15)00041.
    PubMed     Text format     Abstract available


  27. HUNG SW, Marrache S, Cummins S, Bhutia YD, et al
    Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
    Cancer Lett. 2015 Jan 16. pii: S0304-3835(15)00039.
    PubMed     Text format     Abstract available


    December 2014
  28. LEONE V, Ferraro A, Schepis F, Federico A, et al
    The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.
    Cancer Lett. 2014 Dec 9. pii: S0304-3835(14)00753.
    PubMed     Text format     Abstract available


    November 2014
  29. DRINBERG V, Bitcover R, Rajchenbach W, Peer D, et al
    Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine.
    Cancer Lett. 2014;354:290-8.
    PubMed     Text format     Abstract available


  30. DOBERSTEIN K, Bretz NP, Schirmer U, Fiegl H, et al
    miR-21-3p is a positive regulator of L1CAM in several human carcinomas.
    Cancer Lett. 2014;354:455-66.
    PubMed     Text format     Abstract available


  31. KIM TH, Song JY, Park H, Jeong JY, et al
    miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
    Cancer Lett. 2014 Nov 10. pii: S0304-3835(14)00667.
    PubMed     Text format     Abstract available


  32. BILANDZIC M, Wang Y, Ahmed N, Luwor RB, et al
    Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFkappaB-mediated induction of MMP2.
    Cancer Lett. 2014;354:107-14.
    PubMed     Text format     Abstract available


    October 2014
  33. LANGHE R, Norris L, Saadeh FA, Blackshields G, et al
    A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
    Cancer Lett. 2014 Oct 16. pii: S0304-3835(14)00598.
    PubMed     Text format     Abstract available


  34. WARD JD, Ha JH, Jayaraman M, Dhanasekaran DN, et al
    LPA-mediated migration of ovarian cancer cells involves translocalization of Galpha to invadopodia and association with Src and beta-pix.
    Cancer Lett. 2014 Oct 13. pii: S0304-3835(14)00568.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: